|
Approve Suite Weekly · Tuesday, October 13, 2026 · read online
Class I: Medline Industries, LP — Medline Basic Homecare Beds and…
Medline recalls homecare bed hand pendants due to potential fire hazard from overheating wiring. Class I recall of device components poses serious safety risk (fire/burn) to end-users in home settings. Ongoing status indicates the recall is active and additional product lots may be added. Zenas BioPharma announces Phase 2 SLE topline results expected in 4Q 2026 for obexelimab. This is a routine clinical milestone announcement. The company expects Phase 2 SLE trial results in the fourth quarter of 2026 for its B-cell inhibitor obexelimab, which has completed nine trials in 667 subjects to date. The pattern? Recalls led the week with 158, far ahead of trial status changes, 8-K filings, and final rules and guidance, each at 7, out of 183 counted.
This week's author: Ryan Burke, Approve Suite
Class I: Medline Industries, LP — Medline Basic Homecare Beds and Medlite Homecare Beds and Accessories, Hand Pendants: MDR510094 PENDANT F/ MDR107002E MDR520094 PENDANT F/ M…
Class I · Medline Industries, LP
Medline recalls homecare bed hand pendants due to potential fire hazard from overheating wiring.
Why it matters. Class I recall of device components poses serious safety risk (fire/burn) to end-users in home settings. Ongoing status indicates the recall is active and additional product lots may be added.
What to watch. The classification and, later, the termination notice both post to openFDA; Class I recalls also appear as safety alerts.
READ MORE → · open in Approve Suite
|
Presented by Approve Suite
Put a watchlist on this. Name your CDMO and competitors; get these the day they post. $79/mo, no card to start. See pricing →
|
8-K: Zenas BioPharma, Inc. mentions topline results
8-K · Zenas BioPharma, Inc.
Zenas BioPharma announces Phase 2 SLE topline results expected in 4Q 2026 for obexelimab.
Why it matters. This is a routine clinical milestone announcement. The company expects Phase 2 SLE trial results in the fourth quarter of 2026 for its B-cell inhibitor obexelimab, which has completed nine trials in 667 subjects to date.
What to watch. Items 1.01, 2.02 and 8.01 carry the material terms; the exhibits hold the detail.
READ MORE → · open in Approve Suite
|
Presented by Approve Suite
Put a watchlist on this. Name your CDMO and competitors; get these the day they post. $79/mo, no card to start. See pricing →
|
Medical Devices; Cardiovascular Devices; Classification of the Infant Pulse Rate and Oxygen Saturation Monitor for Over-the-Counter Use
Final rule
FDA classifies infant pulse rate and oxygen saturation monitor as Class II device for OTC use.
Why it matters. This final classification establishes the regulatory pathway and special controls for OTC infant pulse oximetry devices, clarifying requirements for manufacturers and reducing barriers to market entry for this monitoring category.
What to watch. The amended text appears in the eCFR on the effective date; procedures that cite the section are the ones affected.
READ MORE → · open in Approve Suite
By the numbers
Inspections: 0 NAI · 0 VAI · 0 OAI Warning letters: 0 Class I recalls: 11 (Class II 146, Class III 1) Trial stops and status changes: 7 (results posted: 3) Raises: 8, $81M disclosed
221 events, down 36% on the prior 7 days.
203 listed companies report under 12 months of runway.
Signals
1. Class I: Medline Industries, LP — Medline Basic Homecare Beds and Medlite Homecare Beds and Accessories MDR107000P BED, MANUAL, MEDLITE Class I · Medline Industries, LP app 2. Class I: Draeger, Inc. — VentStar Resus Neo. Neonatal. 25 Units per Box. Part Number: MP00310 Disposable breathing circuit for use with a resuscitation module. Class I · Draeger app 3. 8-K: Vaxcyte, Inc. mentions Form 483 8-K · Vaxcyte, Inc. app 4. 8-K: X4 Pharmaceuticals, Inc mentions topline results 8-K · X4 Pharmaceuticals app 5. Medical Devices; Immunology and Microbiology Devices; Classification of the Hematopoietic Cell Enrichment Kit Final rule app 6. Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens Final rule app
Why this exists
Approve Suite Weekly exists so a QA or RA lead can read one email on Tuesday and know what FDA, the SEC and ClinicalTrials.gov published in the past week. Every line links to its public source; nothing here is advice.
Sponsor this email
How was this week's email?
AwesomeDecentNot great
| 